Loss of BCAA catabolism with upregulated BCAT1 expression in tumours confers functional advantages, which could be exploited by therapeutic interventions to metabolic reprogramming for more ICC cases beyond genomic diversity. Here, BCAT1 is linked to intrahepatic cholangiocarcinoma.